Darolutamide trial shows 59% reduction in metastasis risk for prostate cancer

New Reference: Neoadjuvant FOLFIRINOX vs. Chemoradiation for Pancreatic Cancer The phase 3 PREOPANC-2 trial found no significant difference in median overall or progression-free survival between neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable or borderline resectable pancreatic cancer. Both regimens showed comparable safety profiles. These results suggest that both treatments can be considered viable options for patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. https://lnkd.in/etM7AQ3U

Check out our new pre-print manuscript on BioRxiv about T cells and blood cancer by Lisa Aziez et al.: Pro-inflammatory Role of Granzyme K-Producing Bystander CD8 T Cells in Acute Myeloid Leukemia In this study, we show that rather mounting an anti-tumor response, CD8+ T cells contribute to a pro-inflammatory environment that may exacerbate acute myeloid leukemia (AML) progression and severity. BioRxiv link: https://lnkd.in/e2__r2tZ

evERA #BreastCancer trial Presented at #ESMO25 Giredestrant an oral selective oestrogen receptor antagonist and degrader, + everolimus in ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor https://lnkd.in/d_PSHRgQ The evERA BC trial demonstrated that Giredestrant plus everolimus significantly improved progression-free survival with a manageable safety profile in patients with ER+, HER2– advanced breast cancer after progression on CDK4/6 inhibitor therapy. Erica Mayer   Sara Tolaney  Miguel Martín Gregory Vidal Komal Jhaveri, MD FACP, FASCO  Adam Brufsky  William Gradishar Naoki Niikura  Anne Favret  Margarita Sonia Alfie Merilin Feldman, PharmD Lisa Lam Walter Darbonne  Pablo Perez-Moreno MD Hope S. Rugo

The evERA BC trial demonstrated that Giredestrant plus everolimus significantly improved progression-free survival with a manageable safety profile in patients with ER+, HER2– advanced #BreastCancer after progression on CDK4/6 inhibitor therapy.

New AusPAR for Pluvicto (lutetium (177Lu) vipivotide tetraxetan) is approved for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Read more: https://lnkd.in/gUbt52RK

New AusPAR for Pluvicto (lutetium (177Lu) vipivotide tetraxetan) is approved for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Read more: https://lnkd.in/gUbt52RK

From #ESMO25: Updated data from the phase 3 #EMBARK trial showed that enzalutamide plus leuprolide significantly improved overall survival compared with leuprolide alone in patients with biochemically recurrent prostate cancer. According to presenting author Stephen Freedland, MD, of Cedars-Sinai, these findings reinforce previous metastasis-free survival data from EMBARK, "show[ing] that enzalutamide with ADT is the standard of care for high-risk, biochemically recurrent prostate cancer patients.” For more 🔗 : https://lnkd.in/eT2QkTJ2

New data from #ESMO25 💡 Findings from the phase 3 IMvigor011 trial show that adjuvant atezolizumab, when guided by ctDNA monitoring, significantly improves both disease-free survival and overall survival in patients with muscle-invasive bladder cancer (#MIBC). The results were presented by Tom Powles, MD, MBBS, MRCP, during the Presidential Symposium at ESMO 2025. Powles explained, "These findings indicate serial ctDNA monitoring identified patients with muscle-invasive bladder cancer who benefit from adjuvant atezolizumab while sparing patients who are persistently negative from unnecessary treatment." For more 🔗 : https://lnkd.in/eNP-mmey

Treatment for bladder cancer depends on type, stage, grade, and risk level. For non-muscle invasive bladder cancer (NMIBC), common approaches include: 🔹 TURBT (transurethral resection of bladder tumor): removes visible tumors and collects tissue for diagnosis 🔹 IVT (intravesical therapy): medication delivered directly into the bladder to reduce recurrence Learn more about bladder cancer treatments: https://lnkd.in/gaWedEhE 

New Reference: Enzalutamide in Biochemically Recurrent Prostate Cancer The trial showed that enzalutamide plus leuprolide significantly improved overall survival compared to leuprolide alone in patients with high-risk biochemically recurrent prostate cancer. The combination reduced the risk of death by 40%. Enzalutamide monotherapy did not significantly improve survival compared to leuprolide alone. https://lnkd.in/eqHhwaJ5